Compare BLFS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLFS | IOVA |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2013 | 2008 |
| Metric | BLFS | IOVA |
|---|---|---|
| Price | $37.22 | $8.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $32.00 | $9.00 |
| AVG Volume (30 Days) | 682.7K | ★ 19.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | 14.84 |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $96,214,000.00 | N/A |
| Revenue This Year | $19.73 | $47.74 |
| Revenue Next Year | $17.82 | $40.31 |
| P/E Ratio | $39.56 | ★ N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $1.76 |
| 52 Week High | $38.10 | $9.36 |
| Indicator | BLFS | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 78.89 | 68.90 |
| Support Level | $23.63 | $3.57 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.93 | 0.65 |
| MACD | 0.09 | 0.17 |
| Stochastic Oscillator | 84.58 | 66.23 |
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.